Skills this job asks for
TranslationLeadershipNegotiation
Add your CV (free) to see which of these your CV is missing.
Sponsorship verdict
Sponsorship possible
One solid signal, not two. Worth applying, and worth asking about sponsorship early.
-
✓
Employer is on a government sponsor recordThe US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Feb 2026) — the step every H-1B hire needs first.
-
?
The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
-
?
No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area.
-
✓
What Lyell Immunopharma INC paid sponsored hires in similar roles1 certified filing for “Senior Director, Medical Affairs, Solid Tumors” (Natural Sciences Managers) in CA: $291k–$291k, median $291k.
-
✓
Confirmed live todayWhen a source last listed this job as open.
Details and sources
- Employer is on a government sponsor record
- The US Department of Labor certified 1 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Feb 2026) — the step every H-1B hire needs first. Source: LCA disclosure data (US Department of Labor (OFLC)).
- No salary bar for this route
- H-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Lyell Immunopharma INC paid sponsored hires in similar roles
- 1 certified filing for “Senior Director, Medical Affairs, Solid Tumors” (Natural Sciences Managers) in CA: $291k–$291k, median $291k. Most were filed at wage level IV (100%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence. It is not legal advice and never a guarantee: the employer and the immigration authority decide. Sign in to factor in where you can already work.
About the role
Using living cells to treat – and sometimes even cure – cancer is one of the most dramatic advances in modern medicine. Patients with hematologic malignancies have been successfully treated with cell therapies. However, these profound results have not yet been achieved in patients with solid tumors, representing approximately 90% of all cancers. And for patients with hematologic malignancies, there is a need for next-generation cell therapies that can deliver increased response rates and longer duration of response. We are a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel technology designed to generate T cells that resist exhaustion and have qualities of durable stemness in order to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical response. We were founded by cell therapy pioneers whose decades of research elevated the broader understanding of T-cell biology and its interaction with cancer. In our quest to advance next-generation CAR T-cell therapies, we have built a fully integrated company capable of discovering new technologies, translating science into therapies, manufacturing cell therapy products, and clinically evaluating them in patients. Our culture is based on Science, Respect, Collaboration, and Courage and reflects who we are, the environment we create, and our mission's urgency.
This role can be remote with regular travel to either our Seattle, WA or South San Francisco, CA offices.
The Director of Regulatory Affairs/Global Regulatory Lead (GRL) will be focusing on the development of cutting-edge CAR-T cell therapies in oncology.
As the GRL, you will define, develop, and execute the global regulatory strategy for assigned CAR-T programs from early clinical development through licensure (BLA/MAA) and lifecycle management. You will serve as the primary regulatory representative to global health authorities (FDA, EMA, etc.), ensuring alignment with business objectives and driving innovative approaches to accelerate the development of transformative therapies for patients.
KEY ROLE AND RESPONSIBILITIES:
Global Regulatory Strategy & Leadership
• Develop & Execute Strategy: Create and lead comprehensive, creative, and innovative global regulatory strategies to support the development and commercialization of CAR-T cell therapy products.
• Represent Regulatory: Represent the Regulatory Team in cross-functional meetings, ensuring alignment with regional regulatory requirements, CMC, and clinical development plans.
• Risk Mitigation: Proactively identify regulatory risks, develop contingency plans, and anticipate hurdles in the evolving CAR-T regulatory landscape.
• Drive Milestones: Accountable for timely submission and approval of global regulatory dossiers (IND, CTA, BLA, MAA).
Health Authority Interactions
• Primary Liaison: Act as the primary point of contact and lead negotiations with regulatory agencies (FDA, EMA, etc.), including managing FDA meetings (Pre-IND, EOP2, Pre-BLA) and briefing document preparation.
• Agency Negotiation: Support regional teams in resolving key regulatory issues to expedite clinical study country expansion.
Cross-Functional Collaboration
• Strategic Input: Partner with CMC, Clinical Development, Translational Medicine, and Medical Affairs teams to align regulatory strategy with scientific breakthroughs and market access goals.
• Content Review: Review and approve key regulatory documents, including clinical protocols, investigator brochures, and non-clinical reports.
• Mentor Staff: Provide coaching and mentoring to junior regulatory staff and other RA team members.
Regulatory Intelligence
• Stay
Apply on employer site ↗